Gefitinib or Erlotinib vs Chemotherapy for EGFR Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall Survival.

Lee CK1, Davies L1, Wu YL1, Mitsudomi T1, Inoue A1, Rosell R1, Zhou C1, Nakagawa K1, Thongprasert S1, Fukuoka M1, Lord S1, Marschner I1, Tu YK1, Gralla RJ1, Gebski V1, Mok T1, Yang JC1.

Author information

Abstract

BACKGROUND:

We performed an individual patient data meta-analysis to examine the impact of first-generation epidermal growth factor receptor ( EGFR ) tyrosine kinase inhibitor (TKI) therapy on overall survival (OS) in advanced non-small cell lung cancer (NSCLC).

METHODS:

Data from trials comparing EGFR-TKI against chemotherapy in exon 19 deletion (del19) or exon 21 L858R (L858R) EGFR mutations patients were used. We performed Cox regression to obtain hazard ratios (HRs) and 95% confidence intervals (CIs). Impact of postprogression therapies was examined in exploratory analyses. All statistical tests were two-sided.

RESULTS:

Six eligible trials (gefitinib = 3, erlotinib = 3) included 1231 patients; 632 received EGFR-TKI and 599 received chemotherapy. At a median 35.0 months follow-up, there were 780 deaths and 1004 progressions. There was no difference in OS between EGFR-TKI and chemotherapy (HR = 1.01, 95% CI = 0.88 to 1.17, P = .84). There was also no difference in OS for Del19 (n = 682, HR = 0.96, 95% CI = 0.79 to 1.16, P = .68) and L858R (n = 540, HR = 1.06, 95% CI = 0.86 to 1.32, P = .59) subgroups ( P interaction = .47), or according to smoking status, sex, performance status, age, ethnicity, or histology. However, EGFR-TKI statistically significantly prolonged progression-free survival (PFS) overall (HR = 0.37, 95% CI = 0.32 to 0.42, P < .001) and in all subgroups. Following progression, 73.8% from the chemotherapy arm received EGFR-TKI, and 65.9% from the EGFR-TKI arm received chemotherapy. Nine percent from the EGFR-TKI arm received no further treatment vs 0.6% from the chemotherapy arm. Following disease progression, patients randomly assigned to EGFR-TKI had shorter OS than those randomly assigned to chemotherapy (12.8 months, 95% CI = 11.4 to 14.3, vs 19.8 months, 95% CI = 17.6 to 21.7).

CONCLUSIONS:

Despite statistically significant PFS benefit, there is no relative OS advantage with frontline gefitinib or erlotinib vs chemotherapy in EGFR -mutated NSCLC. This finding is likely due to the high rate of crossover at progression.

PMID:: 28376144
DOI:: 10.1093/jnci/djw279

From HuGE Literature Finder Database

This database contains published literature on genetic associations and other human genome epidemiology

Gefitinib or Erlotinib vs Chemotherapy for EGFR Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall Survival.
Journal of the National Cancer Institute 2017 Jun 109 (6): .
Lee Chee Khoon, Davies Lucy, Wu Yi-Long, Mitsudomi Tetsuya, Inoue Akira, Rosell Rafael, Zhou Caicun, Nakagawa Kazuhiko, Thongprasert Sumitra, Fukuoka Masahiro, Lord Sally, Marschner Ian, Tu Yu-Kang, Gralla Richard J, Gebski Val, Mok Tony, Yang James Chih-Hs
Low plasma concentration of gefitinib in patients with EGFR exon 21 L858R point mutations shortens progression-free survival.
Cancer chemotherapy and pharmacology 2017 Apr .
Okuda Yuji, Sato Kazuhiro, Sudo Kazuhisa, Hasegawa Yukiyasu, Asano Mariko, Miura Hajime, Takeda Masahide, Sano Masaaki, Watanabe Hiroyuki, Kobayashi Hiroyuki, Niioka Takenori, Miura Masatomo, Ito Hiros
MET exon 14 skipping mutation in triple-negative pulmonary adenocarcinomas and pleomorphic carcinomas: An analysis of intratumoral MET status heterogeneity and clinicopathological characteristics.
Lung cancer (Amsterdam, Netherlands) 2017 Apr 106 131-137.
Kwon Dohee, Koh Jaemoon, Kim Sehui, Go Heounjeong, Kim Young A, Keam Bhumsuk, Kim Tae Min, Kim Dong-Wan, Jeon Yoon Kyung, Chung Doo Hy
MUC1 in lung adenocarcinoma: cross-sectional genetic and serological study.
BMC cancer 2017 Apr 17 (1): 263.
Horimasu Yasushi, Ishikawa Nobuhisa, Tanaka Sonosuke, Hirano Chihiro, Iwamoto Hiroshi, Ohshimo Shinichiro, Fujitaka Kazunori, Hamada Hironobu, Hattori Noboru, Kohno Nobuo
Serum 25(OH)D concentration, common variants of the VDR gene and lung cancer occurrence.
International journal of cancer 2017 Apr .
Gromowski Tomasz, Gapska Paulina, Scott Rodney J, K?klewski Krzysztof, Marciniak Wojciech, Durda Katarzyna, Lener Marcin, Górski Bohdan, Cybulski Cezary, Sukiennicki Grzegorz, Kaczmarek Katarzyna, Jaworska-Bieniek Katarzyna, Paszkowska-Szczur Katarzyna, Waloszczyk Piotr, Lubi?ski Jan, D?bniak Tadeu